|1.||Goldfine, Allison B: 9 articles (11/2015 - 02/2008)|
|2.||Shoelson, Steven E: 8 articles (11/2015 - 02/2008)|
|3.||Jablonski, Kathleen A: 5 articles (05/2014 - 03/2010)|
|4.||Fonseca, Vivian: 4 articles (04/2014 - 03/2010)|
|5.||Almon, Richard R: 3 articles (01/2014 - 12/2011)|
|6.||Jusko, William J: 3 articles (01/2014 - 12/2011)|
|7.||Abbasi, Fahim: 2 articles (09/2015 - 07/2014)|
|8.||Grove, Kaylene: 2 articles (09/2015 - 07/2014)|
|9.||Ariel, Danit: 2 articles (09/2015 - 07/2014)|
|10.||Liu, Alice: 2 articles (09/2015 - 07/2014)|
12/01/2013 - "We conducted an ancillary study to the National Institutes of Health-sponsored, multicenter, randomized, double-masked, placebo-controlled trial evaluating the safety and efficacy of salsalate in targeting inflammation to improve glycemia in patients with T2D. "
02/01/2008 - "The aim of the current study was to evaluate the efficacy of the anti-inflammatory drug salsalate to improve glycemia by reducing systemic inflammation in obese adults at risk for the development of type 2 diabetes. "
03/01/2015 - "Findings suggest that metabolic improvements in response to salsalate occurred without alterations in adiposity, ectopic fat, or adipose tissue gene expression and inflammation."
03/01/2015 - "Plasma markers of inflammation/immune activation were unchanged following salsalate. "
05/01/2014 - "Response to comment on Goldfine et al. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). "
07/01/2014 - "This was a randomized (2:1), single-blind, placebo-controlled study of salsalate (3.5 g daily for 4 weeks) in nondiabetic individuals with insulin resistance. "
12/01/2011 - "Salsalate suppressed both disease factors by a fraction of 0.622 on insulin resistance and 0.134 on β-cell dysfunction. "
07/01/2011 - "High plasma concentrations of FFAs cause both microvascular and metabolic insulin resistance, which can be prevented or attenuated by salsalate treatment. "
07/01/2011 - "Whether salsalate, an anti-inflammatory agent, prevents FFA-induced microvascular and/or metabolic insulin resistance in humans is unknown. "
07/01/2011 - "Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans."
04/01/1995 - "To investigate the efficacy of salsalate, a nonacetylated salicylate, in the treatment of patients with rheumatoid arthritis (RA). "
01/01/1980 - "Long-term management of rheumatoid arthritis with disalcid."
12/01/1989 - "The results of our study support previous observations in patients with rheumatoid arthritis that salsalate produces less gastroduodenal mucosal toxicity than the widely used antiinflammatory agent, naproxen."
07/01/1989 - "A double-blind, double-dummy controlled study to compare the clinical efficacy and gastric tolerability of salsalate and piroxicam in the treatment of rheumatoid arthritis was performed. "
07/01/1989 - "Salsalate in the treatment of rheumatoid arthritis: a double-blind clinical and gastroscopic trial versus piroxicam. "
04/01/2013 - "The frequency of tinnitus was low but tended to be higher with salsalate therapy (n = 4 vs n = 2). "
07/31/2010 - "Tinnitus and transaminitis occurred frequently in the salsalate group. "
07/01/1989 - "Seven (37%) patients treated with salsalate complained of tinnitus. "
09/01/1995 - "This study evaluated physicians' use of the occurrence of tinnitus as a tool to establish the optimal dosage of salsalate, a nonacetylated salicylate, in patients with arthritis treated in routine clinical practice. "
12/01/1989 - "This was due primarily to the higher number of subjects taking salsalate reporting reversible tinnitus or hearing loss. "
01/01/2014 - "The current study determines whether chronic administration (from 5 weeks of age through 24 weeks of age) of salsalate, a salicylate with anti-inflammatory properties, would be effective in mitigating diabetes disease progression in ZDF rats. "
01/01/2014 - "This study investigates the antidiabetic effects of salsalate on disease progression of diabetes in non-obese diabetic Goto-Kakizaki (GK) rats, an experimental model of type 2 diabetes. "
01/01/2014 - "Diabetes disease progression in Goto-Kakizaki rats: effects of salsalate treatment."
12/01/2011 - "Modeling diabetes disease progression and salsalate intervention in Goto-Kakizaki rats."
01/01/2014 - "These results suggest that salsalate acts to both increase adiponectin and decrease adipose tissue-based inflammation while preventing type 2 diabetes disease progression in GK rats. "
|4.||NF-kappa B (NF-kB)
|8.||Aspirin (Acetylsalicylic Acid)
|9.||salicylsalicylic acid (salsalate)
|3.||Renal Dialysis (Hemodialysis)